Welcome back to Diagnostic Accelerator (DxA) Investigator Day!

This year’s meeting promises to be another exciting opportunity for DxA-funded investigators to share and discuss progress on fluid, ocular, speech, and other digital biomarkers for Alzheimer’s.

Due to the complex nature of the disease, the next phase of Alzheimer’s research and treatment will hinge on combination therapy, precision medicine, and lifestyle interventions. As such, diagnostics and biomarkers will be integral to the future of Alzheimer’s care, paving the way for earlier detection and intervention. This year, we will hear from leading scientists, entrepreneurs, startups, investors, and others who are part of this collaborative effort.

Since its launch in 2018, the DxA has fostered a bold vision for developing accessible and affordable biomarkers for Alzheimer’s disease and related dementias by providing resources to the world’s brightest scientists. To date, the $100 million global research initiative has invested more than $60M in nearly 60 global research projects, creating a robust biomarker portfolio. With the FDA approval of Leqembi—the first disease modifying treatment approved for Alzheimer’s—the need for accessible and affordable diagnostic tools becomes even more vital as we look to ensure the right drugs are delivered to the right patients at the right time. Biomarkers have proven vital for every phase of the drug discovery and development process, and further advancing the biomarker pipeline by bringing scalable tests to market will be pivotal as we enter the modern era of Alzheimer’s research.

As always, we are grateful for the vision and support of ADDF Co-Founder Leonard A. Lauder and Bill Gates as well as all funders who bring focus, resources, and urgency to advance the development of diagnostic tools, including the Dolby Family, The Charles and Helen Schwab Foundation, Jeff Bezos, The Association for Frontotemporal Degeneration (AFTD), MacKenzie Scott, The NFL Players Association (NFLPA), Eli Lilly & Company, Biogen, The Shanahan Family Foundation, and others.

We hope you will take this opportunity to connect and collaborate, exchanging ideas to further accelerate research for a future free from Alzheimer’s. We look forward to a thought-provoking and insightful meeting.

Sincerely,